Skip to main content

Drug Interactions between antivenin (micrurus fulvius) and Vyduo

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

antivenin (Micrurus fulvius) nebivolol

Applies to: antivenin (micrurus fulvius) and Vyduo (nebivolol / valsartan)

MONITOR: Beta-adrenergic blockers (including ophthalmic formulations) may increase the severity and duration of acute anaphylactic reactions to antivenins. In addition, anaphylaxis may be resistant to the usual treatment modalities. The mechanism is unknown.

MANAGEMENT: Patients should be closely monitored for signs of severe, acute hypersensitivity reactions during administration of antivenins, and facilities and equipment for resuscitation, cardiovascular support, and airway management should be immediately available. Clinicians should be aware that larger doses of epinephrine or other adrenergic agents may be required.

References (2)
  1. "Product Information. CroFab (antivenin (Crotalidae) polyvalent)." Savage Laboratories
  2. (2022) "Product Information. Antivenin (Latrodectus mactans) (antivenin (black widow spider))." Merck & Co., Inc

Drug and food interactions

Moderate

valsartan food

Applies to: Vyduo (nebivolol / valsartan)

GENERALLY AVOID: Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs). ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion. Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.

MANAGEMENT: Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician. If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended. Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.

References (2)
  1. (2001) "Product Information. Cozaar (losartan)." Merck & Co., Inc
  2. (2001) "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer